Dice CEO: Energy, T...
Health Care: Drugs
BioMarin Pharmaceuticals Inc (BMRN: NASDAQ)
$35.53 -0.11 | -0.31%
06/01/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 441.36M | 376.27M | 324.66M | 296.49M |
| Cost of Sales | 43.89M | 44.50M | 47.85M | 45.74M |
| Gross Operating Profit | 397.46M | 331.77M | 276.81M | 250.76M |
| Selling, General, and Administrative Expenses | 175.42M | 151.72M | 124.29M | 106.57M |
| Research & Development | 214.37M | 147.31M | 115.12M | 93.29M |
| Operating Income before D & A (EBITDA) | 7.67M | 32.73M | 37.40M | 50.90M |
| Depreciation & Amortization | 40.13M | 32.19M | 20.98M | 11.14M |
| Interest Income | 2.93M | 4.11M | 5.09M | 16.39M |
| Other Income - Net | -1.90M | -12.83M | -4.26M | -4.06M |
| Special Income / Charges | -1.43M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -35.28M | -11.16M | 14.66M | 49.82M |
| Interest Expense | 8.35M | 10.33M | 14.09M | 16.39M |
| Pre-Tax Income | -43.63M | -21.49M | 566.00K | 33.42M |
| Income Taxes | 10.21M | -227.31M | 1.05M | 2.59M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -53.84M | 205.82M | -488.00K | 30.83M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -53.84M | 205.82M | -488.00K | 30.83M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -53.84M | 205.82M | -488.00K | 30.83M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-52.41M | 205.82M | -488.00K | 30.83M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -53.84M | 205.82M | -488.00K | 30.83M |
| Basic EPS from Continuing Ops. | -0.48 | 2.00 | 0.00 | 0.31 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.48 | 2.00 | 0.00 | 0.31 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.48 | 2.00 | 0.00 | 0.31 |
| Basic Normalized Net Income/Share | -0.47 | 2.00 | n.a. | 0.31 |
| EPS fr Continuing Ops. | -0.48 | 1.73 | 0.00 | 0.29 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.48 | 1.73 | 0.00 | 0.29 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.48 | 1.73 | 0.00 | 0.29 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.47 | 1.73 | n.a. | 0.29 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with BMRN
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- ContributorStocks Rising On Unusual Vo...
- UserScottrade IRA
- UserEverett Bishop Portfolio 1
- ContributorEarnings Short Squeeze Play...
- Userwjwallace Portfolio
- ContributorStocks At New 52-Week Highs...
- ProColumbia Wanger Asset Manag...
- Contributor21 Stocks to Watch
- ContributorBreakout Stocks Of The Week...
Latest BMRN Headlines from TheStreet
- BioMarin Stock Falls On Unusually High Volume (BMRN) 05.31.12 | 02:05 pm
- BioMarin Stock Hits New 52-Week High (BMRN) 05.29.12 | 10:05 am
- 8 Stocks Rising on Big Volume 05.21.12 | 01:05 pm
- 5 Stocks Hit 52-Week Highs 05.16.12 | 01:05 pm
- BioMarin Stock Hits New 52-Week High (BMRN) 05.16.12 | 09:05 am
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.27.12 | 03:04 am
- BioMarin Pharmaceutical's CEO Discusses Q4 2011 Earning Results - Earnings Call Transcript 02.16.12 | 11:02 pm
- 5 Earnings Stocks Poised to Pop 02.16.12 | 12:02 pm
- BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
Press Releases for BMRN
- IU Confidential Publishes Biotech Investment Report - PR Newswire 07.28.11 | 09:07 am
- BioMarin Launches Firdapse In The European Union - PR Newswire 04.19.10 | 09:04 am
- BioMarin To Present At The Barclays Capital Global Healthcare Conference - PR Newswire 03.17.10 | 09:03 am
- BioMarin To Acquire LEAD Therapeutics - PR Newswire 02.04.10 | 04:02 pm
Partner Headlines for BMRN
- BioMarin Prices Share Offering - Analyst Blog - Zacks 06.01.12 | 05:06 pm
- Analyst Insights: Finish Line, BioMarin Pharma, Laboratory Corp, Ocz Technology, AstraZeneca May 31st - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- 9 High-Liquidity Mid Caps Poised For Growth - Seeking Alpha 05.28.12 | 08:05 am
- Loss at BioMarin Wider Than Expected - Analyst Blog - Zacks 02.17.12 | 09:02 am
- Zacks Bull and Bear of the Day Highlights: ProAssurance, BioMarin Pharmaceutical, Diebold, Vodafone and United Parcel Services - Press Releases - Zacks 02.14.12 | 09:02 am
- BioMarin Pharmaceutical (BMRN) - Bear of the Day - Zacks 02.14.12 | 01:02 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 02.08.12 | 09:02 am
- BioMarin's Facility Expansion Backed - Analyst Blog - Zacks 12.22.11 | 10:12 am
- Facility Expansion at BioMarin - Analyst Blog - Zacks 11.29.11 | 10:11 am
- Activist Hedge Fund Accipiter Capital's Top Stock Picks - Seeking Alpha 11.29.11 | 09:11 am
